Skip to main content

Table 1 Characteristics of included studies

From: Clinical safety of total glucosides of paeony adjuvant therapy for rheumatoid arthritis treatment: a systematic review and meta-analysis

Study ID Patients Treatment Control Course of treatment
Intervention N M/F Age
(Mean ± SD)
Duration of disease (Years) Intervention N M/F Age
(Mean ± SD)
Duration of disease (Years)
Lin 2016 Patients with RA MTX + TGP 50 20/30 43.9 ± 5.1 3.5 ± 0.5 MTX 50 20/30 43.7 ± 5.2 3.3 ± 0.6 24 weeks
Yin 2007 Patients with RA MTX + TGP 30 MTX 30 12 weeks
Gong 2017 Patients with RA MTX + TGP 40 15/25 67.2 ± 5.2 1.3 MTX 40 17/23 68.8 ± 5.8 1.3 3 months
Chen 2017 Patients with RA MTX + TGP 40 18/22 32.8 ± 4.9 2.2 ± 0.2 MTX 40 21/19 32.4 ± 5.3 2.2 ± 0.2 24 weeks
Fan 2006 Patients with EORA MTX + TGP 34 8/26 MTX 32 7/25 24 weeks
Min 2005 Patients with RA MTX + TGP 117 24/93 46.0 ± 13.0 2.4 ± 4.3 MTX 52 17/35 44.0 ± 14.0 2.0 ± 3.3 48 weeks
Du 2005 Patients with RA MTX + TGP 31 20/11 40.0 ± 6.4 6.8 ± 3.6 MTX 30 18/12 38.0 ± 7.8 4.5 ± 3.2 12 weeks
Sun 2011 Patients with JRA MTX + TGP 26 12/14 7.6 MTX 25 12/13 8.0   26 weeks
Shang 2009 Patients with RA MTX + TGP 31 11/20 40.0 ± 6.0 4.0 ± 3.0 MTX 28 9/19 39.0 ± 6.0 4.0 ± 3.0 12 weeks
Wang 2012 Patients with JRA MTX + TGP 31 20/11 10.9 ± 3.3 1.9 ± 1.2 MTX 30 18/12 10.2 ± 2.4 1.8 ± 1.3 12 weeks
Liu 2007 Patients with RA MTX + TGP 46 MTX 44 24 weeks
Wang 2020 Patients with RA MTX + TGP 36 16/20 42.8 ± 11.4 13 ± 2.5 MTX 46 17/29 42.8 ± 11.4 12 ± 2 24 weeks
Guo 2020 Patients with RA MTX + TGP 43 16/27 51.58 ± 3.1 1–14 MTX 43 17/26 51.02 ± 3.16 1-12 12 weeks
Zhu 2009 Patients with RA MTX + TGP 23 6/17 46 ± 12 MTX 23 7/16 47 ± 11 24 weeks
Ma 2009 Patients with RA LEF + TGP 40 LEF 40 12 weeks
Yu 2010 Patients with RA LEF + TGP 39 11/28 39.0 ± 11.0 1.8 ± 0.8 LEF 40 9/31 46.0 ± 10.0 2.1 ± 0.9 24 weeks
Li 2014 Patients with EORA LEF + TGP 48 18/30 59.9 ± 6.1 3.9 ± 2.1 LEF 48 20/28 60.2 ± 5.8 4.1 ± 1.9
Han 2016 Patients with EORA LEF + TGP 42 18/24 5.8 ± 7.2 5.36 ± 2.1 LEF 42 12/30 66.2 ± 7.4 5.5 ± 2.3 24 weeks
Wu 2015 Patients with RA LEF + TGP 50 10/40 LEF 50 8/42 12 weeks
Zhao 2006 Patients with RA LEF + TGP 40 18/22 31.0 ± 8.9 4.0 ± 3.8 LEF 40 14/26 30.0 ± 9.6 5.0 ± 4.9 12 weeks
Zhang 2016 Patients with RA MTX + LEF + TGP 43 31/12 45.5 ± 4.4 6.3 ± 2.5 MTX + LEF 43 29/14 45.7 ± 4.2 6.1 ± 2.4 3 months
Yu 2018 Patients with RA MTX + LEF + TGP 42 15/27 58.6 ± 7.5 5.4 ± 1.6 MTX + LEF 38 13/25 58.4 ± 7.5 5.4 ± 1.6 4 weeks
Wang 2011 Patients with RA MTX + LEF + TGP 33 MTX + LEF 31 12 weeks
Wang YP 2012 Patients with RA MTX + LEF + TGP 33 MTX + LEF 31 16 weeks
Wang 2015 Patients with RA MTX + LEF + TGP 40 MTX + LEF 40 12 weeks
Chen 2013 Patients with RA MTX + LEF + TGP 105 MTX + LEF 89 24 weeks
Xiang 2015 Patients with RA MTX + LEF + TGP 132 26/106 49.6 ± 12.6 2.2 MTX + LEF 136 39/97 47.6 ± 11.7 2 12 weeks
Tan 2018 Patients with RA MTX + LEF + TGP 56 19/28 58.4 ± 4.6 8.9 ± 4.3 MTX + LEF 52 20/25 56.8 ± 5.1 10.1 ± 4.5 24 weeks
Xu 2018 Patients with RA MTX + LEF + TGP 45 15/30 53.46 ± 3.45 5.84 ± 0.35 MTX + LEF 45 16/29 53.76 ± 3.13 5.22 ± 0.28 12 weeks
Yu HY 2018 Patients with RA MTX + LEF + TGP 40 24/16 47.18 ± 6.92 10.8 ± 3.6 MTX + LEF 40 23/17 47.33 ± 6.67 11.2 ± 3.5 36 weeks
Ju 2019 Patients with RA MTX + LEF + TGP 60 21/39 40.12 ± 4.37 4.59 ± 0.53 MTX + LEF 60 23/37 39.81 ± 4.42 4.63 ± 0.46 24 weeks
Zhang 2019 Patients with RA MTX + LEF + TGP 50 28/22 59.62 ± 6.82 5.38 ± 1.56 MTX + LEF 50 30/20 59.71 ± 6.75 5.91 ± 1.42 12 weeks
Liu 2019 Patients with RA MTX + LEF + TGP 49 25/24 51.62 ± 3.47 2.95 ± 0.64 MTX + LEF 49 26/23 51.75 ± 3.26 2.97 ± 0.58 12 weeks
Zhang XL 2019 Patients with RA MTX + LEF + TGP 135 41/94 43.12 ± 9.56 MTX + LEF 133 40/93 43.12 ± 9.56 12 weeks
Zhang 2005 Patients with RA TG + TGP 30 3/27 51.4 ± 15.2 4.0 ± 3.5 TG 30 2/28 53.6 ± 13.7 3.2 ± 3.2 3 months
Zhang C 2016 Patients with RA MLX + TGP 49 25/24 57.0 ± 7.5 MLX 41 21/20 56.0 ± 6.5 12 weeks
Huang 2014 Patients with RA SSZ + TGP 30 SSZ 60 8 weeks
Shen 2018 Patients with RA IGU + TGP 30 IGU 30 12 weeks
Li 2020 Patients with RA PAT+TGP 35 21/14 51.40 ± 4.76 18.67 ± 5.12 PAT 35 15/20 51.52 ± 4.82 18.75 ± 5.16 12 weeks
\